K-ras基因突变非小细胞肺癌临床治疗现状及研究进展  

Status quo and research progress of treatment for patients with K-ras gene mutation complicated with non-small cell lung cancer

作　　者：张甜甜 王婕 田应选[2] Zhang Tiantan;Wang Jie;Tian Yingxuan(Graduate School of Xi'an Medical College,Xi'an 710021 China;Department of Geriatric Respiratory Medicine,Shaanxi Provincial People's Hospital,Xi'an 710068,China)

机构地区：[1]西安医学院研究生院,西安710021 [2]陕西省人民医院老年呼吸科,西安710068

出　　处：《国际呼吸杂志》2022年第17期1356-1360,共5页International Journal of Respiration

基　　金：陕西省人民医院拔尖人才支持计划(2021BJ-22);科技部重点研发项目(2018YFC2002100、2018YFC2002103);陕西省科技厅自然科学重点研究项目(2022JZ-59)。

摘　　要：肺癌已成为我国乃至全球发病率第二、病死率最高的实体恶性肿瘤,非小细胞肺癌(NSCLC)是其中最主要的病理类型。随着新一代测序技术(NGS)的应用,K-ras基因突变越来越受到临床关注。本文从K-ras基因的信号通路、在NSCLC中相关的临床作用、新药开发和应用及未来的研究方向几个方面进行综述,并对K-ras突变NSCLC研究和诊治提供依据。Lung cancer has emerged asthe solid malignant tumor with the second morbidity and highest mortalityin China and even the world,and non-small cell lung cancer(NSCLC)is considered to be theuppermost leading pathological type for lung cancer.K-ras gene mutations draw increasing more clinical concerns with the application of next-generation sequencing technology(NGS).The Paper reviews the signaling pathway of K-ras genes,correspondingclinical role in NSCLC,development and application of new pharmaceuticals,and futureresearch orientation,and provides thebasis for research,diagnosis and treatment of K-ras mutation complicated with NSCLC.

关 键 词：癌 非小细胞肺 K-RAS基因突变 信号通路 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]